BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 21515798)

  • 1. IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-alpha-mediated bone loss.
    Zaiss MM; Kurowska-Stolarska M; Böhm C; Gary R; Scholtysek C; Stolarski B; Reilly J; Kerr S; Millar NL; Kamradt T; McInnes IB; Fallon PG; David JP; Liew FY; Schett G
    J Immunol; 2011 Jun; 186(11):6097-105. PubMed ID: 21515798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells.
    Schulze J; Bickert T; Beil FT; Zaiss MM; Albers J; Wintges K; Streichert T; Klaetschke K; Keller J; Hissnauer TN; Spiro AS; Gessner A; Schett G; Amling M; McKenzie AN; Horst AK; Schinke T
    J Bone Miner Res; 2011 Apr; 26(4):704-17. PubMed ID: 20939024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro.
    Saleh H; Eeles D; Hodge JM; Nicholson GC; Gu R; Pompolo S; Gillespie MT; Quinn JM
    Endocrinology; 2011 May; 152(5):1911-22. PubMed ID: 21363931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation.
    Kurowska-Stolarska M; Stolarski B; Kewin P; Murphy G; Corrigan CJ; Ying S; Pitman N; Mirchandani A; Rana B; van Rooijen N; Shepherd M; McSharry C; McInnes IB; Xu D; Liew FY
    J Immunol; 2009 Nov; 183(10):6469-77. PubMed ID: 19841166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population.
    Nagata N; Kitaura H; Yoshida N; Nakayama K
    Bone; 2003 Oct; 33(4):721-32. PubMed ID: 14555278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory T cells protect from local and systemic bone destruction in arthritis.
    Zaiss MM; Frey B; Hess A; Zwerina J; Luther J; Nimmerjahn F; Engelke K; Kollias G; Hünig T; Schett G; David JP
    J Immunol; 2010 Jun; 184(12):7238-46. PubMed ID: 20483756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the liver X receptor-β potently inhibits osteoclastogenesis from lipopolysaccharide-exposed bone marrow-derived macrophages.
    Robertson Remen KM; Lerner UH; Gustafsson JÅ; Andersson G
    J Leukoc Biol; 2013 Jan; 93(1):71-82. PubMed ID: 23099324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.
    Kobayashi K; Takahashi N; Jimi E; Udagawa N; Takami M; Kotake S; Nakagawa N; Kinosaki M; Yamaguchi K; Shima N; Yasuda H; Morinaga T; Higashio K; Martin TJ; Suda T
    J Exp Med; 2000 Jan; 191(2):275-86. PubMed ID: 10637272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling.
    Kalliolias GD; Zhao B; Triantafyllopoulou A; Park-Min KH; Ivashkiv LB
    Arthritis Rheum; 2010 Feb; 62(2):402-13. PubMed ID: 20112358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular basis of requirement of receptor activator of nuclear factor κB signaling for interleukin 1-mediated osteoclastogenesis.
    Jules J; Zhang P; Ashley JW; Wei S; Shi Z; Liu J; Michalek SM; Feng X
    J Biol Chem; 2012 May; 287(19):15728-38. PubMed ID: 22416138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acteoside suppresses RANKL-mediated osteoclastogenesis by inhibiting c-Fos induction and NF-κB pathway and attenuating ROS production.
    Lee SY; Lee KS; Yi SH; Kook SH; Lee JC
    PLoS One; 2013; 8(12):e80873. PubMed ID: 24324641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-4 directly inhibits tumor necrosis factor-alpha-mediated osteoclast formation in mouse bone marrow macrophages.
    Kitaura H; Nagata N; Fujimura Y; Hotokezaka H; Tatamiya M; Nakao N; Yoshida N; Nakayama K
    Immunol Lett; 2003 Sep; 88(3):193-8. PubMed ID: 12941478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
    Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
    Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
    Kanazawa K; Kudo A
    J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-3 and granulocyte-macrophage colony-stimulating factor inhibits tumor necrosis factor (TNF)-alpha-induced osteoclast differentiation by down-regulation of expression of TNF receptors 1 and 2.
    Yogesha SD; Khapli SM; Wani MR
    J Biol Chem; 2005 Mar; 280(12):11759-69. PubMed ID: 15653694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct osteoclast precursors in the bone marrow and extramedullary organs characterized by responsiveness to Toll-like receptor ligands and TNF-alpha.
    Hayashi S; Yamada T; Tsuneto M; Yamane T; Takahashi M; Shultz LD; Yamazaki H
    J Immunol; 2003 Nov; 171(10):5130-9. PubMed ID: 14607912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage.
    Khapli SM; Mangashetti LS; Yogesha SD; Wani MR
    J Immunol; 2003 Jul; 171(1):142-51. PubMed ID: 12816992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-128 plays a critical role in murine osteoclastogenesis and estrogen deficiency-induced bone loss.
    Shen G; Ren H; Shang Q; Zhang Z; Zhao W; Yu X; Tang J; Yang Z; Liang D; Jiang X
    Theranostics; 2020; 10(10):4334-4348. PubMed ID: 32292498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo.
    Axmann R; Böhm C; Krönke G; Zwerina J; Smolen J; Schett G
    Arthritis Rheum; 2009 Sep; 60(9):2747-56. PubMed ID: 19714627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of tumor necrosis factor α and interleukin-6 induces mouse osteoclast-like cells with bone resorption activity both in vitro and in vivo.
    Yokota K; Sato K; Miyazaki T; Kitaura H; Kayama H; Miyoshi F; Araki Y; Akiyama Y; Takeda K; Mimura T
    Arthritis Rheumatol; 2014 Jan; 66(1):121-9. PubMed ID: 24431283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.